Aarey Drugs

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 26-Aug, Aarey Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 80.88, up 5.0%, driven by strong daily performance, increased investor participation, and robust historical returns. The stock has outperformed its sector and shows significant gains year-to-date and over the past year.

As of 26-Aug, Aarey Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 80.88, reflecting an increase of Rs 3.85 or 5.0%. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed its sector by 5.38% today, indicating strong relative performance. It reached an intraday high of Rs 80.88, which is a 5% increase, suggesting positive momentum in trading. Additionally, there has been a notable increase in investor participation, with a delivery volume of 77.8k on 25 August, which is up by 7.55% compared to the 5-day average delivery volume. This increase in trading activity often signals growing investor interest and confidence in the stock.<BR><BR>Furthermore, the stock has shown strong performance over longer periods, with a year-to-date increase of 19.50% and a one-year increase of 32.48%, significantly outperforming the Sensex, which has declined by 9.09% and 4.10% respectively during those periods. Such historical performance can contribute to positive sentiment among investors, further driving the stock price up.<BR><BR>In summary, the combination of strong daily performance, increased investor participation, and robust historical returns are key factors contributing to the rise in Aarey Drugs & Pharmaceuticals Ltd's stock price.

Which are the latest news on Aarey Drugs?

Should I buy, sell or hold Aarey Drugs & Pharmaceuticals Ltd?

Who are in the management team of Aarey Drugs?

The management team of Aarey Drugs includes Mihir R Ghatalia (Chairman & Managing Director), Chetan K Mehta, Lalit Tulsiani, and Anil Mandal (Independent Directors), Preeti Paresh Rathi (Company Secretary & Compliance Officer), Nimit R Ghatalia (Executive Director), and Bina Ghatalia (Additional Director).

The management team of Aarey Drugs includes the following individuals:<BR><BR>1. Mihir R Ghatalia - Chairman & Managing Director<BR>2. Chetan K Mehta - Independent Director<BR>3. Preeti Paresh Rathi - Company Secretary & Compliance Officer<BR>4. Lalit Tulsiani - Independent Director<BR>5. Nimit R Ghatalia - Executive Director<BR>6. Anil Mandal - Independent Director<BR>7. Bina Ghatalia - Additional Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Aarey Drugs do?

Aarey Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 189 Cr and a net profit of 2 Cr for March 2026. It was established in 1990 and has a market cap of INR 253 Cr.

Overview:<BR>Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 1990 as Niharika Textiles & Chemicals Private Limited and underwent a name change after being taken over by the Aarey Group in 1993, converting to a public limited company. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 189 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 253 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 56.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.32 <BR>Return on Equity: 3.00% <BR>Price to Book: 1.69 <BR><BR>Contact Details:<BR>Address: E-34 MIDC Tarapur, Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-23455543 <BR>Website: http://www.aareydrugs.com

Who are the peers of the Aarey Drugs?

Aarey Drugs' peers include BDH Industries, Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab., Lyka Labs, Oxygenta Pharma, Sanjiv.Parant., and Gennex Lab. Aarey Drugs has below average management risk and growth, with a 1-year return of 26.86%, compared to BDH Industries' highest return of 92.22% and Lyka Labs' lowest at -34.01%.

Peers: The peers of Aarey Drugs are BDH Industries, Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab., Lyka Labs, Oxygenta Pharma, Sanjiv.Parant., and Gennex Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries and Sanjiv.Parant., while Average management risk is found at Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab., Lyka Labs, and Gennex Lab. Below Average management risk is noted for Aarey Drugs. Growth is Excellent at Trident Lifeline and Good at Astonea Labs and Sanjiv.Parant., while Below Average growth is seen at BDH Industries, Everest Organics, Aarey Drugs, Lyka Labs, and Zenotech Lab. The rest have Average growth. Capital Structure is Excellent at BDH Industries and Zenotech Lab., Good at Trident Lifeline and Sanjiv.Parant., and Below Average at Aarey Drugs, Everest Organics, Astonea Labs, Lyka Labs, and Gennex Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 92.22%, while the lowest is Lyka Labs at -34.01%. Aarey Drugs has a 1-year return of 26.86%, which is significantly higher than Lyka Labs but lower than BDH Industries. Additionally, the peers with negative six-month returns include Everest Organics, Zenotech Lab., Lyka Labs, and Gennex Lab.

How big is Aarey Drugs?

As of 14th August, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 251.93 Cr, with recent net sales of 472.27 Cr and a net profit of 4.52 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 251.93 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 472.27 Cr, while the sum of Net Profit for the same period is 4.52 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 138.48 Cr, and Total Assets amount to 290.59 Cr.

When is the next results date for Aarey Drugs & Pharmaceuticals Ltd?

The next results date for Aarey Drugs & Pharmaceuticals Ltd is 14 August 2026.

The next results date for Aarey Drugs & Pharmaceuticals Ltd is scheduled for 14 August 2026.

Are Aarey Drugs & Pharmaceuticals Ltd latest results good or bad?

Aarey Drugs & Pharmaceuticals Ltd's latest results show strong revenue growth, with Q4 FY26 net sales up 96.48% quarter-on-quarter, but profitability remains a concern, with low margins and modest net profit, indicating operational challenges despite impressive sales figures.

Aarey Drugs & Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported impressive revenue growth, with net sales reaching ₹189.47 crores in Q4 FY26, marking a 96.48% increase quarter-on-quarter and a 75.27% increase year-on-year. This is the highest quarterly revenue in the company's recent history, indicating strong sales momentum.<BR><BR>However, the profitability metrics raise concerns. The net profit for the same quarter was ₹1.56 crores, which, despite being a significant 173.68% increase from the previous quarter and a 231.91% increase year-on-year, remains modest relative to the revenue base. The operating profit margin is quite low at 2.29%, and the profit after tax (PAT) margin is a mere 0.82%, which is among the weakest in the pharmaceutical sector.<BR><BR>Additionally, the company faces structural challenges, as it struggles to convert revenue growth into sustainable profits. The return on equity is low at 4.20%, and the return on capital employed is even lower at 2.55%. These figures suggest that while the company is generating revenue, it is not effectively managing costs or leveraging its growth to enhance profitability.<BR><BR>In summary, while Aarey Drugs has shown strong revenue growth, the underlying profitability issues and low margins indicate that the results are not entirely positive. The company appears to be in a challenging position, balancing impressive sales figures with significant operational weaknesses.

How has been the historical performance of Aarey Drugs?

Aarey Drugs has experienced fluctuating financial performance, with net sales increasing to 473.94 Cr in March 2025 from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. Profitability metrics, including operating profit and earnings per share, have generally declined, indicating challenges in maintaining consistent profitability.

Answer:<BR>The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profitability over the years, with net sales reaching 473.94 Cr in March 2025, up from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. The total operating income followed a similar pattern, peaking at 492.68 Cr in March 2022 before declining to 473.94 Cr in March 2025. The operating profit (PBDIT) has also seen a decline, from 14.02 Cr in March 2022 to 12.70 Cr in March 2025. Profit before tax increased slightly to 6.10 Cr in March 2025 from 5.34 Cr in March 2024, while profit after tax decreased to 4.02 Cr in March 2025 from 4.68 Cr in March 2024. The company's earnings per share (EPS) dropped to 1.43 in March 2025 from 1.67 in March 2024, reflecting the overall decline in profitability.<BR><BR>Breakdown:<BR>Aarey Drugs' financial performance has shown variability in key metrics over the years. Net sales increased from 395.62 Cr in March 2024 to 473.94 Cr in March 2025, although this is a decrease from the 492.68 Cr recorded in March 2022. Total operating income mirrored this trend, with a peak in March 2022 before falling to 473.94 Cr in March 2025. Operating profit (PBDIT) has declined from 14.02 Cr in March 2022 to 12.70 Cr in March 2025, indicating a downward trend in profitability. Profit before tax saw a slight increase to 6.10 Cr in March 2025, while profit after tax decreased to 4.02 Cr in the same period. The earnings per share (EPS) also fell to 1.43 in March 2025 from 1.67 in March 2024, reflecting the challenges faced by the company in maintaining profitability amidst fluctuating sales and operating income.

Is Aarey Drugs overvalued or undervalued?

As of November 17, 2025, Aarey Drugs is considered overvalued with a high PE ratio of 75.88, weak profitability indicated by a 2.47% ROE, and negative operational metrics, despite recent strong stock performance.

As of 17 November 2025, Aarey Drugs has moved from a fair to a risky valuation grade. The company appears to be overvalued, primarily indicated by its high PE ratio of 75.88 and an EV to EBITDA ratio of 134.14, which are significantly above industry norms. Additionally, the return on equity (ROE) stands at a mere 2.47%, reflecting weak profitability, while the EV to EBIT ratio is notably negative at -315.22, suggesting severe operational challenges.<BR><BR>In comparison to its peers, Aarey Drugs' valuation metrics are concerning. For instance, Elitecon International has a PE ratio of 294.38, indicating a very expensive valuation, while PTC India, which is considered very attractive, has a PE of just 7.56. Aarey Drugs' high valuation ratios, combined with its negative ROCE of -0.07%, further underscore its overvaluation status. Despite recent strong stock performance against the Sensex, with a year-to-date return of 68.93% compared to the Sensex's 8.72%, the underlying financial metrics suggest that the stock may not sustain its current price levels.

Who are the top shareholders of the Aarey Drugs?

The top shareholders of Aarey Drugs include promoter Bina Rajesh Ghatalia with 14.12%, and the highest public shareholder, India Opportunities Growth Fund Ltd - Pinewood, with 2.34%. Individual investors hold 45.79%, and there is one foreign institutional investor with 2.34%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Aarey Drugs include Bina Rajesh Ghatalia, who is the promoter with the highest holding at 14.12%. Additionally, the highest public shareholder is India Opportunities Growth Fund Ltd - Pinewood, holding 2.34%. The company also has individual investors holding a significant portion at 45.79%. Furthermore, there is one foreign institutional investor (FII) that holds 2.34% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

What is the technical trend for Aarey Drugs?

As of June 5, 2025, Aarey Drugs shows a neutral technical stance with mixed signals: weekly indicators are bullish while daily trends are mildly bearish, suggesting caution despite potential upward movement indicated by Bollinger Bands.

As of 5 June 2025, the technical trend for Aarey Drugs has changed from mildly bearish to sideways. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds caution. The KST shows a bullish stance weekly but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with a mildly bullish monthly outlook. Overall, the current technical stance is neutral, with strength in the weekly indicators but caution from daily trends.

What is the bonus history of the Aarey Drugs?

Aarey Drugs & Pharmaceuticals Ltd issued a 1:5 bonus on June 25, 2012, granting shareholders one additional share for every five shares held, with a record date of June 26, 2012. This is the company's most recent bonus action.

Aarey Drugs & Pharmaceuticals Ltd has a bonus history that includes a notable issue on June 25, 2012. The company announced a 1:5 bonus issue, meaning that for every five shares held, shareholders received one additional share. The record date for this bonus was June 26, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Aarey Drugs or need further details, feel free to ask!

Has Aarey Drugs declared dividend?

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend, amounting to ₹0.10 per share, with an ex-date of December 13, 2018. Despite the dividend declaration, the dividend yield is 0%, and total returns over various periods show significant price appreciation, especially over five years.

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.10<BR>- Ex-date: 13 Dec 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -12.92%, the dividend return was 0%, resulting in a total return of -12.92%.<BR><BR>For the 1 year period, the price return was 21.16%, the dividend return was 0%, leading to a total return of 21.16%.<BR><BR>Over the 2 years period, the price return was 66.72%, the dividend return was 0%, culminating in a total return of 66.72%.<BR><BR>In the 3 years period, the price return was 50.85%, the dividend return was 0%, which resulted in a total return of 50.85%.<BR><BR>For the 4 years period, the price return was 55.93%, the dividend return was 0%, yielding a total return of 55.93%.<BR><BR>In the 5 years period, the price return was 155.4%, the dividend return was 0%, resulting in a total return of 155.4%.<BR><BR>Overall, Aarey Drugs has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with significant price returns in the longer term, particularly over 5 years.